Vitamin D, selenium, and antidiabetic drugs in the treatment of type 2 diabetes mellitus with Hashimoto's thyroiditis

Table 2 Comparison of thyroid function pre-treatment and after 3 and 6 months of treatment in the three groups

Group	TSH (mU/L)			FT3 (pmol/L)			FT4 (pmol/L)
	Pre-treatment	After 3 months of treatment	After 6 months of treatment	Pre-treatment	After 3 months of treatment	After 6 months of treatment	Pre-treatment	After 3 months of treatment	After 6 months of treatment
Control group (n = 50)	14.50 ± 2.30	13.29 ± 2.34	12.89 ± 2.18	2.39 ± 0.77	2.57 ± 0.83	2.65 ± 0.82	7.35 ± 1.35	8.27 ± 1.45	8.96 ± 2.05
Test group A (n = 50)	14.49 ± 2.23	8.37 ± 2.33a	4.98 ± 1.45a	2.43 ± 0.80	3.98 ± 0.86a	5.21 ± 1.26a	7.28 ± 1.38	11.27 ± 2.16a	15.51 ± 2.40a
Test group B (n = 50)	14.70 ± 2.34	8.54 ± 2.41a,b	4.05 ± 1.27a,b	2.48 ± 0.81	4.05 ± 0.90a,b	5.47 ± 1.34a,b	7.26 ± 1.26	11.87 ± 2.27a,b	16.91 ± 2.73a,b
F value	0.133	70.399	416.857	0.162	47.220	89.340	0.063	52.264	155.329
P value	0.875	< 0.001	< 0.001	0.850	< 0.001	< 0.001	0.939	< 0.001	< 0.001

^aP < 0.05 vs group pre-treatment.

^bP < 0.05 vs 3 months after treatment.

TSH: Thyroid-stimulating hormone; FT3: Free T3; FT4: Free T4